Yarchoan, M., Chan, S. L., Edeline, J., Li, D., Bomba, D., Jenkins, Y., Smith, S., Standifer, N., Vogel, A., Whiting, S. H. (2025). PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4214